Antimicrobial peptides against polymyxin-resistant Klebsiella pneumoniae: a patent review.
Antimicrobial therapies
Gram-negative bacteria
Multidrug-resistant
Journal
World journal of microbiology & biotechnology
ISSN: 1573-0972
Titre abrégé: World J Microbiol Biotechnol
Pays: Germany
ID NLM: 9012472
Informations de publication
Date de publication:
01 Feb 2023
01 Feb 2023
Historique:
received:
14
12
2022
accepted:
19
01
2023
entrez:
31
1
2023
pubmed:
1
2
2023
medline:
3
2
2023
Statut:
epublish
Résumé
The spread of polymyxin-resistant Klebsiella pneumoniae strains represents an emerging health challenge, limiting treatment options for the patients. Thus, the development of new antimicrobials is an urgent requirement. Antimicrobial peptides (AMPs) are a large class of compounds that are part of innate immune response; these peptides are promising compounds in the field of antimicrobial resistance and are present in all organisms. The present review evaluated patents on antimicrobial peptides tested against polymyxin-resistant K. pneumoniae, available on Espacenet as of September 2022. A total of 1313 patents were examined and 1197 excluded as they were out of focus for this review; 104 patents of peptides tested against K. pneumoniae were included; of which only 14 were tested against polymyxin-resistant K. pneumoniae strains. The results indicated that all AMPs evaluated were in the experimental or pre-clinical phase; the clinical phase is pending. Furthermore, a few peptides were tested effectively against polymyxin-resistant K. pneumoniae. Although, the research and patent filing alone are not enough to develop a suitable antimicrobial therapy, they can represent good starting point upon which to develop new antimicrobials. More investment is required to push these pharmaceuticals through the stages of development to introduce them into the market.
Identifiants
pubmed: 36720739
doi: 10.1007/s11274-023-03530-6
pii: 10.1007/s11274-023-03530-6
pmc: PMC9889241
doi:
Substances chimiques
Antimicrobial Peptides
0
Polymyxins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Subventions
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : 001
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 001
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 001
Organisme : Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul
ID : 71/031.898/2022
Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Crit Rev Biotechnol. 2021 Mar;41(2):229-248
pubmed: 33530749
Front Microbiol. 2020 Jan 22;10:3097
pubmed: 32038544
Int J Med Microbiol. 2020 Oct;310(7):151448
pubmed: 33092694
FEMS Microbiol Rev. 2017 May 1;41(3):252-275
pubmed: 28521338
Int J Mol Sci. 2021 Jul 31;22(15):
pubmed: 34361008
Clin Microbiol Rev. 2020 May 13;33(3):
pubmed: 32404435
J Antimicrob Chemother. 2021 Apr 13;76(5):1174-1186
pubmed: 33501992
Mil Med Res. 2021 Sep 9;8(1):48
pubmed: 34496967
Nat Microbiol. 2019 Apr;4(4):565-577
pubmed: 30833727
Front Med Technol. 2022 Jan 25;3:778645
pubmed: 35146486
Front Chem. 2018 Aug 14;6:309
pubmed: 30155456
Nat Rev Microbiol. 2020 Jun;18(6):344-359
pubmed: 32055025
Expert Opin Ther Pat. 2020 Dec;30(12):931-947
pubmed: 33187458
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):461-475
pubmed: 33009595
Pharmaceutics. 2021 Mar 24;13(4):
pubmed: 33804947
Nature. 2018 Sep;561(7722):189-194
pubmed: 30209367
Nat Rev Drug Discov. 2021 Apr;20(4):309-325
pubmed: 33536635
BMC Microbiol. 2022 Feb 7;22(1):47
pubmed: 35130831
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Antibiotics (Basel). 2021 Mar 10;10(3):
pubmed: 33801833
Biomedicines. 2021 Oct 03;9(10):
pubmed: 34680498
Future Microbiol. 2013 Jun;8(6):711-24
pubmed: 23701329
Front Cell Infect Microbiol. 2018 Jan 22;8:4
pubmed: 29404282
Int J Mol Sci. 2016 May 03;17(5):
pubmed: 27153059
N Biotechnol. 2021 Jan 25;60:124-129
pubmed: 33091617
mBio. 2016 Sep 20;7(5):
pubmed: 27651360
Microbiol Spectr. 2021 Dec 22;9(3):e0123121
pubmed: 34730415
Trends Microbiol. 2021 Jan;29(1):65-83
pubmed: 32448764
Clin Infect Dis. 2017 Mar 15;64(6):711-718
pubmed: 27940944
Nat Microbiol. 2020 Aug;5(8):1040-1050
pubmed: 32424338
Infect Dis Ther. 2021 Mar;10(1):75-92
pubmed: 33492641
Int J Antimicrob Agents. 2011 May;37(5):480-4
pubmed: 21353493
Shock. 2008 Oct;30 Suppl 1:30-3
pubmed: 18704012
Pharmaceuticals (Basel). 2013 Nov 28;6(12):1543-75
pubmed: 24287494
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769122
Int J Environ Res Public Health. 2020 Aug 28;17(17):
pubmed: 32872324
Antibiotics (Basel). 2021 Aug 14;10(8):
pubmed: 34439031
Future Med Chem. 2020 Nov;12(22):2035-2065
pubmed: 33169622
J Med Chem. 2017 Dec 14;60(23):9630-9640
pubmed: 29136469
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172